Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06356129 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | PHASE3 | ACTIVE NOT_RECRUITING | 850 | — | — | Jun 19, 2024 | Nov 20, 2029 | Feb 12, 2026 | 325 | United States, Argentina +36 |
| Arm | Type | Description |
|---|---|---|
| Golcadomide + R-CHOP (Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone) | EXPERIMENTAL | - |
| Placebo + R-CHOP | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Golcadomide | DRUG | Specified dose on specified days |
| Placebo | DRUG | Specified dose on specified days |
| Rituximab | DRUG | Specified dose on specified days |
| Cyclophosphamide | DRUG | Specified dose on specified days |
| Doxorubicin | DRUG | Specified dose on specified days |
| Vincristine | DRUG | Specified dose on specified days |
| Prednisone | DRUG | Specified dose on specified days |
Inclusion Criteria \- Histologically confirmed (per local evaluation) diagnosis of de novo, previously untreated large B-cell lymphoma (LBCL) according to 2022 world health organization (WHO) classification including: i) Diffuse large B-cell lymphoma (DLBCL), not otherwise specified \[including ge...